Search

Your search keyword '"Miloradovic, V."' showing total 44 results

Search Constraints

Start Over You searched for: Author "Miloradovic, V." Remove constraint Author: "Miloradovic, V."
44 results on '"Miloradovic, V."'

Search Results

1. The timing of death in acute pulmonary embolism patients regarding the mortality risk stratification at admission to hospital

2. The dose-dependent effect of chronic Verapamil treatment on cardiac function in isolated rat heart with Hypertension

3. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey

4. P561Acute effects of dronedarone and amiodarone on functional, morphological and oxidative stress parameters in isolated rat heart with hypertension

5. P6465Are we calculated enough? Glomerular filtration rate as a predictor of intra-hospital prognosis in patients with pulmonary embolism

6. P5591Efficacy and safety of lower dose slow infusion of t-PA for intermediate-risk pulmonary embolism patients with risk for bleeding

7. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients

8. Edoxaban versus warfarin in patients with atrial fibrillation

9. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial

10. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy

11. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

12. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

13. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

14. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

15. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

16. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

17. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

18. PP.37.12

19. PP.37.19

20. PP.01.34

21. PP.37.24

26. The timing of death in acute pulmonary embolism patients regarding the mortality risk stratification at admission to the hospital.

27. Association of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism.

28. New-Onset Paroxysmal Atrial Fibrillation in the Setting of Acute Pulmonary Embolism Is Associated with All-Cause Hospital Mortality in Women but Not in Men.

29. Signs and symptoms of acute pulmonary embolism and their predictive value for all-cause hospital death in respect of severity of the disease, age, sex and body mass index: retrospective analysis of the Regional PE Registry (REPER).

30. The Role of Bioelectrical Impedance Analysis in Predicting COVID-19 Outcome.

31. Pulmonary embolism bleeding score index (PEBSI): A new tool for the detection of patients with low risk for major bleeding on thrombolytic therapy.

32. Predictive value of admission glycemia in diabetics with pulmonary embolism compared to non-diabetic patients.

33. Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism.

34. Sex-related difference in the prognostic value of syncope for 30-day mortality among hospitalized pulmonary embolism patients.

35. Renal dysfunction as intrahospital prognostic indicator in acute pulmonary embolism.

36. Biomarkers for the prediction of early pulmonary embolism related mortality in spontaneous and provoked thrombotic disease.

37. Association of coronary ischemia estimated by fractional flow reserve and psychological characteristics of patients.

38. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes.

39. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.

40. Identifying culprit lesions in non-ST-elevation myocardial infarction: are new diagnostic tools always better?

41. Knuckle technique guided by intravascular ultrasound for in-stent restenosis occlusion treatment.

42. Coronary spasm that caused non-ST elevation myocardial infarction appeared in cath lab due to vasovagal reaction.

43. Numerical simulation of the flow field and mass transport pattern within the coronary artery.

44. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes.

Catalog

Books, media, physical & digital resources